Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name MYCLo-5
   Synonyms LPP-AS2, MYCLo-5, MYCLo-6
   Region GRCh38_3:188151206-188154057    Sequence
   Ensembl ENSG00000270959
   RefSeq NR_036497
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name hepatocellular carcinoma
   ICD-0-3 C22.0  M8170/3
   Methods qPCR, Flow cytometry assay, Cell proliferation assay etc.
   Sample cell lines (HCT116, RKO, HT29, A549, PC3, MCF7 and SKBR3, SK-HEP-1 and HepG2)
   Expression Pattern down-regulated
   Function Description

Of the tested cell lines, MYCLo-4 was upregulated by MYC knockdown in HCT116 (CRC), RKO (CRC), HT29 (colorectal adenocarcinoma), A549 (Lung carcinoma) and PC3 (prostate cancer). The other 2 lncRNAs, MYCLo-5 and -6 were also induced by MYC repression in various cancer types such as CRC (HCT116, RKO and HT29), lung cancer (A549), prostate cancer (PC3), breast cancer (MCF7 and SKBR3) and hepatocellular carcinoma (SK-HEP-1 and HepG2).

   Pubmed ID 26003165
   Year 2015
   Title MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression.
   External Links
   Links for  MYCLo-5 GenBank       HGNC       lncrnadb       Noncode
   Links for  hepatocellular carcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.